Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 PB Ratio is 17.19 as of Aug. 01, 2026, which is 22% above its 10-year median of 14.13. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 921 Drug Manufacturers companies, Corona Remedies ranks worse than 96.42% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-01), Corona Remedies's share price is ₹2098.80. Corona Remedies's Book Value per Share for the quarter that ended in Mar. 2026 was ₹122.12. Hence, Corona Remedies's PB Ratio of today is 17.19.
Warning Sign:
Corona Remedies Ltd stock PB Ratio (=17.3) is close to 1-year high of 17.3.
The historical rank and industry rank for Corona Remedies's PB Ratio or its related term are showing as below:
NSE:CORONA'
s PB Ratio Range Over the Past 10 Years
Min: 12.28 Med: 14.13 Max: 17.32
Current: 17.32
During the past 4 years, Corona Remedies's highest PB Ratio was 17.32. The lowest was 12.28. And the median was 14.13.
NSE:CORONA's PB Ratio is ranked worse than 96.42% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs NSE:CORONA: 17.32
During the past 12 months, Corona Remedies's average Book Value Per Share Growth Rate was 23.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 22.30% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Corona Remedies was 22.30% per year. The lowest was 22.30% per year. And the median was 22.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Corona Remedies PB Ratio Related Terms
Corona Remedies PB Ratio Historical Data
* Premium members only.
The historical data trend for Corona Remedies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Corona Remedies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Corona Remedies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Corona Remedies's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Corona Remedies (NSE:CORONA) has a PB Ratio of 17.19 as of Aug. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corona Remedies and its competitors. This is 22% above median its historical median of 14.13. Over the past decade, Corona Remedies' PB Ratio has ranged from 12.28 to 17.32. According to the industry distribution chart, Corona Remedies ranks #888 out of 921 companies in the Drug Manufacturers industry, placing it in the top 96.4%.
Is Corona Remedies' PB Ratio too high?
Corona Remedies' current PB Ratio of 17.19 is 22% above median its 10-year median of 14.13. Over the past 10 years, this metric has ranged from a low of 12.28 to a high of 17.32. The Drug Manufacturers industry median PB Ratio is 1.88. Corona Remedies' value of 17.19 is 814.4% above this industry median. Based on the distribution chart, Corona Remedies ranks #888 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #888 out of 921 companies for PB Ratio. This places Corona Remedies in the lower half of its industry. The industry median PB Ratio is 1.88. Corona Remedies' value of 17.19 is 814.4% above this benchmark. Historically, Corona Remedies' own PB Ratio has ranged from 12.28 to 17.32 over the past decade. While the company's 10-year median is 14.13 vs. the industry median of 1.88, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current PB Ratio of 17.19 is 814.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current PB Ratio is 17.19, which is 22% above median its own 10-year median of 14.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current PB Ratio of 17.19. The current PB Ratio is 17.19, which is 22% above median its 10-year median of 14.13 and 814.4% above the Drug Manufacturers industry median of 1.88. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current PB Ratio is 17.19 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
